Lineage Cell Therapeutics (LCTX) Tops Q1 EPS by 2c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $391 thousand versus the consensus estimate of $350 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Piper Sandler lists 5 chip stocks to buy
• Shoe Station Group Inc. (SHOE) Tops Q2 EPS by 11c ; Offers Guidance
• Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance